This section is intended exclusively for healthcare professionals
Please note that the content is intended solely for scientific information purposes and does not constitute advertising.
I confirm that I am a healthcare professional.
Loading component...
Loading component...
MDT Live 2026
Introduction to Artificial Intelligence (AI)
The Oncotype DX® testing strategy in multifocal HR+, HER2- breast cancer
From Biopsy to Decision: How pre-operative the Oncotype DX® test can support the patient care pathway
Genomics in the CDK4/6 Era
N2 Disease
Navigating chemotherapy and ovarian function in a young node-negative patient
Breast Cancer in Pregnancy
ER-low disease: Navigating treatment decisions at the boundary of luminal and triple negative biology
Loading component...
MDT Live Focus: Helping guide treatment decisions in HR+, HER2-, early breast cancer patients
This MDT Live Focus session explores how genomic testing on core biopsy samples can support earlier, more informed treatment decisions in HR+, HER2- early breast cancer. Discover how integrating these insights into the diagnostic phase may help guide surgical planning and enable more personalized patient pathways.
Loading component...
Enhancing personalized care in HR+ early breast cancer: How MGA’s help to individualize risk-based systemic treatment decisions
This ESMO Breast Cancer 2026 Industry Satellite Symposium highlights the growing role of multigene assays in tailoring treatment for HR+ early breast cancer. Gain insights into how genomic risk assessment can support more precise, individualized systemic therapy decisions.
Prognosis vs Prediction: does high-risk mean high response?
Understanding prognosis is not the same as predicting treatment benefit. In this session, explore how multigene assays help distinguish between risk and response, supporting more precise decisions on chemotherapy use and helping to avoid both over- and undertreatment in HR+, HER2- early breast cancer.
Incorporating genomic testing when considering adjuvant CDK4/6 inhibitors
Treatment decisions are rarely driven by a single factor. This session explores how multigene assay results can be combined with clinical and patient characteristics to guide chemotherapy use and may help inform CDK4/6 inhibitor decisions, supporting a more nuanced and individualized treatment approach in HR+ early breast cancer.
Where are we with personalized approaches for node-positive patients?
Node-positive disease no longer means a uniform treatment approach. This session explores how integrating genomic risk assessment with dynamic biomarkers can help refine treatment decisions, identify patients who may safely avoid chemotherapy, and support more personalized care in HR+, HER2- early breast cancer.
Loading component...
Deciding Together: How Multigene Assays support Shared Decision Making in early breast cancer
How confident are your treatment decisions in early breast cancer? In this satellite symposium, explore how genomic insights can help reduce uncertainty, support personalized discussions, and align treatment choices with what matters most to your patients.
Loading component...
MDT Live 2025
Helping guide treatment decisions in HR+, HER2-, early breast cancer patients
AC vs TAC Chemotherapy in High Recurrence Score® Patients
HR+, HER2- early breast cancer patient with lower clinical risk
HR+, HER2-, early breast cancer patient - current consideration of CDK4/6 options
ER-low to ER-negative
The role of testing before surgery and the potential impact on treatment planning
Practicalities on core biopsy – Pre-DX
Integrating patient-reported outcomes into decision-making
Further de-escalation in early breast cancer
Updated N0 Oncotype DX® Patient Report
Loading component...
MDT Live October 2024
Helping guide treatment decisions in HR+, HER2-, early breast cancer patients
Loading component...
MDT Live March 2024
Our 2nd in the series where breast cancer clinicians come together to discuss HR+, HER2- early invasive breast cancer cases.
Loading component...
Loading component...
Shaping the future of treatment decision making using Multigene Assays (MGA): An expert round table
Focus on the Pre-Operative Genomic Testing was one of the Key Messages from the Exact Sciences Symposium at St. Gallen 2025. The session also included expert contributions from key opinion leaders where topics like systemic treatment decision-making, neoadjuvant strategies, and patient engagement were shared.
Directing Neoadjuvant Chemotherapy (NAC) using the Oncotype DX Breast Recurrence Score Result
Professor, Stephen Chia MD, FRCP(C)
Optimizing systemic treatment choices using the Oncotype DX Breast Recurrence Score Result pre-operatively
Professor Shani Paluch-Shimon
Genomic testing on excision sample vs core biopsy: What we can learn from PreDX?
Henry Cain
Patient perspectives: A round table discussion
Henry Cain
Loading component...
Welcome and Introduction
Professor Marc A. Thill
Unlocking the Oncotype DX Breast Recurrence Score® Test: Unique design and development to bring clarity to treatment decisions
Professor Frédérique Penault-Llorca
Advancing treatment approaches and neoadjuvant therapy in early breast cancer: Evidence-based strategies
Professor Marc A. Thill
Emerging Trends on Treatment Guidance in Early Breast Cancer: Unveiling clinical implications from latest updates from TAILORx and RxPONDER
Professor Christos Sotiriou
Loading component...
Evolving clinical practice for multi-gene assays: what’s new!
Gain insights from esteemed speakers Giuseppe Curigliano, Laura Biganzoli, and Christian Kurzeder as they discuss the implications and implementation of guidelines for MGAs in clinical practice, including expert discussion on challenging cases.
Implications of updated guidelines for MGAs: Introduction
Professor Giuseppe Curigliano provided with an overview of key takeaways from recently updated ESMO Guidelines and St. Gallen recommendation, focusing on MGA and their roles.
Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour
Professor Giuseppe Curigliano presented a challenging case study of early breast cancer with a large tumour, focusing on the use of ODX on Core Biopsy testing.
Implementation of guidelines into clinical practice: expert discussion on challenging cases - Elderly patient
Professor Laura Biganzoli presented a challenging case study of an elderly patient with early breast cancer, focusing on the important interplay between genomic tools and patients’ characteristics.
Challenging cases: N1 – premenopausal
Professor Christian Kurzeder presented a challenging case study of a N1 premenopausal patient, focusing on how ODX and clinical evidence may help guiding the treatment decision.
Loading component...
Insights from ESMO24 - Exact Sciences Educational Symposium
Tools to Guide Treatment Decisions in Early Breast Cancer: Genomic Testing and Emerging Role of MRD
![[ESMO24] Insights from ESMO24.](/_next/image?url=%2F-%2Fjssmedia%2Fproject%2Fheadless%2Foncotype%2Fen%2Fimages%2Fnews-and-resources%2Fvideos%2Fthumbnail_video_esmo24_insights.png%3Fh%3D610%26iar%3D0%26w%3D1084%26rev%3D-1%26hash%3DB553353133A38AA41F242A200B4038BB&w=3840&q=75)
Evolving role of MRD guided decision making in early breast cancer
Prof. Sherene Loi presented at ESMO 2024 an update on the current data and ongoing studies on molecular residual disease in early breast cancer.
![[ESMO24] Evolving role of MRD guided decision making in early breast cancer.](/_next/image?url=%2F-%2Fjssmedia%2Fproject%2Fheadless%2Foncotype%2Fen%2Fimages%2Fnews-and-resources%2Fvideos%2Fthumbnail_video_esmo24_evolvingroleofmrd.png%3Fh%3D607%26iar%3D0%26w%3D1087%26rev%3D-1%26hash%3D0A6FC36CB77666BDB6DEFC71B501E975&w=3840&q=75)
Tissue-based genomics to guide adjuvant therapy decisions
Prof. Janice Walshe discusses the impact of the introduction of genomic assays on clinical practice for both clinicians and patients.
![[ESMO24] Tissue-based genomics to guide adjuvant therapy decisions.](/_next/image?url=%2F-%2Fjssmedia%2Fproject%2Fheadless%2Foncotype%2Fen%2Fimages%2Fnews-and-resources%2Fvideos%2Fthumbnail_video_esmo24_tissue.png%3Fh%3D610%26iar%3D0%26w%3D1093%26rev%3D-1%26hash%3D0A6590BB05ABB45028B1521CBCD649C8&w=3840&q=75)
Introduction to MRD in breast cancer
Prof. Nicholas Turner provides a brief overview of the concept and terms related to molecular residual disease
![[ESMO24] Introduction to MRD in breast cancer.](/_next/image?url=%2F-%2Fjssmedia%2Fproject%2Fheadless%2Foncotype%2Fen%2Fimages%2Fnews-and-resources%2Fvideos%2Fthumbnail_video_esmo24_introductiontomrd.png%3Fh%3D608%26iar%3D0%26w%3D1093%26rev%3D-1%26hash%3D9CACF5AF7A448C23791F0D1B57EBEFB6&w=3840&q=75)
Evolving role of genomic assays in early breast cancer
Prof. Miguel Martin discusses the application of genomic assays in the neoadjuvant setting
![[ESMO24] Evolving role of genomic assays in early breast cancer.](/_next/image?url=%2F-%2Fjssmedia%2Fproject%2Fheadless%2Foncotype%2Fen%2Fimages%2Fnews-and-resources%2Fvideos%2Fthumbnail_video_esmo24_evolving.png%3Fh%3D611%26iar%3D0%26w%3D1081%26rev%3D-1%26hash%3DA2D776E9CBAC6C05BB60AEE6667DE0F8&w=3840&q=75)
Landmark RxPONDER Trial results presented at the 2020 SABCS
New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0-25.
Get in touch
Have questions about the Oncotype DX test?
